Icelanders, whose unusually low genetic variability makes them ideal for
studies on the origin of diseases, have agreed to reveal the secrets of their
genes to pharmaceuticals company Hoffmann-La Roche. The deal, worth $200
million, gives the company and its partner—deCode Genetics of
Reykjavik—exclusive rights to develop drugs from the genetic data of
Iceland’s population. In return, Icelanders will receive any resulting medicines
free.
More from New ¾«¶«´«Ã½
Explore the latest news, articles and features
Life
Himalayan wolf-dog hybrids emerge as a threat to wolves and people
News
Environment
First test of CO2 removal with green sand finds no harm to marine life
News
Space
SpaceX is about to launch tallest and most powerful rocket in history
News
Environment
Cleaning up air pollution could weaken vital AMOC ocean current
News
Popular articles
Trending New ¾«¶«´«Ã½ articles
1
Why autism pioneer Uta Frith wants to dismantle the spectrum
2
SpaceX is about to launch tallest and most powerful rocket in history
3
Himalayan wolf-dog hybrids emerge as a threat to wolves and people
4
A new tectonic plate boundary could be forming in southern Africa
5
Where did the laws of physics come from? I think I've found the answer
6
Melting of Greenland ice sheet could release methane 'fire ice'
7
CAR T-cell therapy bolstered by stiffening up cancer cells first
8
First test of CO2 removal with green sand finds no harm to marine life
9
Can cloud seeding save us from water bankruptcy?
10
PCOS has been officially renamed PMOS, and it’s a momentous move
